{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:25:21Z","timestamp":1788193521495,"version":"build-2803163510"},"reference-count":31,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Chimeric antigen receptor (CAR) T-cell therapy has transformed haematological-malignancy care, but its dermatologic safety profile remains incompletely characterised across products and indications. Methods: We analysed 8,431,841 deduplicated FDA Adverse Event Reporting System reports from 2016 Q3 to 2026 Q1. Seven approved CAR T-cell products were identified. The primary outcome was any dermatologic adverse event, defined using the MedDRA Skin and subcutaneous tissue disorders system organ class. Secondary outcomes included broad severe cutaneous adverse reactions, narrow Stevens-Johnson syndrome\/toxic epidermal necrolysis, and 14 phenotype-specific categories. Multivariable models adjusted for demographics, polypharmacy, cancer, immune checkpoint inhibitor exposure, lymphodepleting chemotherapy and cytokine release syndrome. Additional sensitivity analyses evaluated HSCT\/GVHD co-reporting proxies, infection and cytopenia\/bleeding proxies, severe-event clinical characteristics, comparator robustness and multiplicity correction. Results: Dermatologic adverse events were identified in 996,654 reports, including 425 CAR-T-associated cases. CAR T-cell exposure was associated with reduced adjusted reporting odds for the primary outcome (adjusted odds ratio 0.13, 95% confidence interval 0.09\u20130.20) and broad severe cutaneous adverse reactions (0.35, 0.23\u20130.52). The primary SKIN_ANY reduced-reporting pattern was consistent across all-FAERS, haematological-malignancy and active haematology-oncology comparators. HSCT\/GVHD proxy co-reporting was uncommon and did not materially alter estimates. Severe dermatologic reports frequently co-mentioned CRS and serious outcomes. The tisagenlecleucel vascular cutaneous signal was nominally significant but attenuated after excluding infection-attributable and cytopenia\/bleeding-proxy reports. Conclusions: Within spontaneous reporting systems, CAR T-cell therapy showed reduced relative reporting of dermatologic adverse events across broad, phenotype-specific and product-level analyses. These results should be interpreted as differences in reporting behaviour, not as evidence of reduced true clinical incidence or lower patient-level risk. Early severe cutaneous reports frequently overlapped with cytokine release syndrome, while infection, cytopenia\/bleeding proxies and supportive-care drugs were important alternative explanations for selected cutaneous signals.<\/jats:p>","DOI":"10.3390\/cancers18132128","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:50:37Z","timestamp":1782867037000},"page":"2128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Dermatologic Adverse Events of CAR T-Cell Therapy: A Decade-Wide Disproportionality Analysis of the FDA Adverse Event Reporting System"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-5158","authenticated-orcid":false,"given":"Manideepa","family":"Maji","sequence":"first","affiliation":[{"name":"Hull York Medical School, University of Hull, Hull HU6 7RX, UK"},{"name":"Haematology, Hull University Teaching Hospitals NHS Trust, Hull HU16 5JQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-5295","authenticated-orcid":false,"given":"Saikat","family":"Mandal","sequence":"additional","affiliation":[{"name":"Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK"},{"name":"NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkadeep","family":"Dhali","sequence":"additional","affiliation":[{"name":"Sheffield Teaching Hospitals NHS Trust, Sheffield S5 7AU, UK"},{"name":"School of Medicine, Dentistry and Biomedical Sciences, Queen\u2019s University Belfast, Belfast BT9 7BL, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[{"name":"Yale New Haven Hospital, New Haven, CT 06510, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: Recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2016.06.062","article-title":"Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy","volume":"75","author":"Rubin","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2021.07.017","article-title":"Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists","volume":"87","author":"Nusbaum","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_6","first-page":"1035.e1","article-title":"Dermatologic Adverse Events Associated With Chimeric Antigen Receptor T-Cell Therapy: A Pharmacovigilance Analysis of the FDA Reporting System","volume":"30","author":"Storgard","year":"2024","journal-title":"Transpl. Cell. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41408-026-01471-5","article-title":"Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies","volume":"16","author":"Umyarova","year":"2026","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lickefett, B., Chu, L., Ortiz-Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D., Hudecek, M., Kremer, A., and Markman, J. (2023). Lymphodepletion\u2014An essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1303935"},{"key":"ref_9","unstructured":"U.S. Food and Drug Administration (2026, May 17). FDA Adverse Event Reporting System (FAERS) Database, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers-database."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Khaleel, M.A., Khan, A.H., Ghadzi, S.M.S., Adnan, A.S., and Abdallah, Q.M. (2022). A Standardized Dataset of a Spontaneous Adverse Event Reporting System. Healthcare, 10.","DOI":"10.3390\/healthcare10030420"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/biomet\/66.3.403","article-title":"Logistic disease incidence models and case-control studies","volume":"66","author":"PRENTICE","year":"1979","journal-title":"Biometrika"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1001\/jamaoncol.2025.4349","article-title":"Immune Checkpoint Inhibitors as Independent and Synergistic Drivers of SJS\/TEN","volume":"11","author":"Mukherjee","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/00001648-199209000-00012","article-title":"Confidence interval estimation of interaction","volume":"3","author":"Hosmer","year":"1992","journal-title":"Epidemiology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ije\/dyr218","article-title":"Recommendations for presenting analyses of effect modification and interaction","volume":"41","author":"Knol","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"ref_16","unstructured":"Health Canada (2026, May 11). Canada Vigilance Adverse Reaction Online Database, Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/adverse-reaction-database.html."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Frantz, R., Huang, S., Are, A., and Motaparthi, K. (2021). Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina, 57.","DOI":"10.3390\/medicina57090895"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","article-title":"Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"key":"ref_25","first-page":"955","article-title":"Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transpl. Cell. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: A model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: From mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.18596","article-title":"Endothelial activation predicts disseminated intravascular coagulopathy, cytokine release syndrome and prognosis in patients treated with anti-CD19 CAR-T cells","volume":"201","author":"Galli","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., Sakellari, I., Gavriilaki, M., and Anagnostopoulos, A. (2020). A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113886"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cutroneo, P.M., Sartori, D., Tuccori, M., Crisafulli, S., Battini, V., Carnovale, C., Rafaniello, C., Capuano, A., Poluzzi, E., and Moretti, U. (2024). Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul., 3.","DOI":"10.3389\/fdsfr.2023.1323057"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:18:12Z","timestamp":1783484292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/13\/2128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":31,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18132128"],"URL":"https:\/\/doi.org\/10.3390\/cancers18132128","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}